Collegium Pharmaceutical
COLL
238 hedge funds and large institutions have $1.06B invested in Collegium Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 71 increasing their positions, 92 reducing their positions, and 46 closing their positions.
155% more call options, than puts
Call options by funds: $707K | Put options by funds: $277K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.39% less ownership
Funds ownership: 119.55% → 115.16% (-4.4%)
4% less funds holding
Funds holding: 249 → 238 (-11)
22% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 46
23% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 92
28% less capital invested
Capital invested by funds: $1.49B → $1.06B (-$423M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$36.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$9.57M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$7.34M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.33M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$14.8M |
| 2 |
Goldman Sachs
New York
|
-$11.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.8M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$10.7M |
| 5 |
JP Morgan Chase
New York
|
-$6.44M |
COLL Hedge Fund Activity: Q4 2024 in Review
238 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2024, worth a combined $1.06B — down 28% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of COLL and 36 opened new positions — a net loss of 10 holders — while 92 trimmed existing stakes and 71 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $36.4M. The largest seller was Pacer Advisors, cutting an estimated $14.8M.
- 238 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2024, down from 249 in Q3 2024.
- Funds reported $1.06B of Collegium Pharmaceutical stock for Q4 2024, down 28% quarter-over-quarter.
- 36 funds opened new Collegium Pharmaceutical positions in Q4 2024 and 46 closed out, a net change of -10 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2024 was Rubric Capital Management (New York), an estimated $36.4M added.
- The largest Collegium Pharmaceutical seller in Q4 2024 was Pacer Advisors, an estimated $14.8M sold.
Based on aggregated 13F filings for Q4 2024.